Skip to content

Study · Measured the body's own peptide · 2013

1 result

Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.

Tenorio-Laranga J, Peltonen I, Keskitalo S, Duran-Torres G, Natarajan R, Männistö PT, Nurmi A, Vartiainen N, Airas L, Elovaara I, García-Horsman JA

Biochemical pharmacology30 Apr 2013Cited by 22 (Europe PMC)

PMID23643808 (opens in a new tab)DOI10.1016/j.bcp.2013.04.018 (opens in a new tab)PepBankPUB-23643808
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01LabEndogenous levelIn vitro (cells)Mechanism

    In cell cultures, prolyl oligopeptidase stimulated immune cells, possibly by modifying the levels of thymosin beta‑4 among other proteins, with no direction stated.

    In plain wordsIn cells, PREP may change the body's own thymosin beta‑4 level, along with other proteins. The direction was not stated.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Direction not reportedThymosin beta-4 level in PREP-stimulated immune cells
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In cell cultures, we found that PREP specifically stimulates immune active cells possibly by modifying the levels of fibrinogen β, thymosin β4, and collagen.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.